These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25743245)

  • 1. Plasma immune analytes in patients with epithelial ovarian cancer.
    Block MS; Maurer MJ; Goergen K; Kalli KR; Erskine CL; Behrens MD; Oberg AL; Knutson KL
    Cytokine; 2015 May; 73(1):108-13. PubMed ID: 25743245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
    Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
    Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer.
    Zacharakis D; Thomakos N; Biliatis I; Rodolakis A; Simou M; Daskalakis G; Bamias A; Antsaklis A
    Acta Obstet Gynecol Scand; 2013 Mar; 92(3):285-92. PubMed ID: 23193945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer.
    Wang T; Zhang Z; Xing H; Wang L; Zhang G; Yu N; Wang J; Guo W; Jiang J
    Medicine (Baltimore); 2017 Oct; 96(43):e8359. PubMed ID: 29069020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
    Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
    Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.
    Pils D; Tong D; Hager G; Obermayr E; Aust S; Heinze G; Kohl M; Schuster E; Wolf A; Sehouli J; Braicu I; Vergote I; Van Gorp T; Mahner S; Concin N; Speiser P; Zeillinger R
    BMC Cancer; 2013 Apr; 13():178. PubMed ID: 23551967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer.
    Carlson AM; Maurer MJ; Goergen KM; Kalli KR; Erskine CL; Behrens MD; Knutson KL; Block MS
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1730-5. PubMed ID: 23878295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
    Luo Y; Kim HS; Kim M; Lee M; Song YS
    J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
    Zhu Q; Wu X; Wu Y; Wang X
    Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
    Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
    Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
    Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.
    Yigit R; Figdor CG; Zusterzeel PL; Pots JM; Torensma R; Massuger LF
    Eur J Cancer; 2011 Aug; 47(12):1883-9. PubMed ID: 21514148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer.
    Wang B; Yu L; Yang GZ; Luo X; Huang L
    Asian Pac J Cancer Prev; 2015; 16(7):3003-7. PubMed ID: 25854397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.